Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 2/20 | 0.72 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.57 |
| ▸ | HTR7 | P34969 | 5/20 | 0.57 |
| ▸ | DRD2 | P14416 | 4/20 | 0.57 |
| ▸ | HTR2A | P28223 | 5/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7822460 | 1.00 | HTR2B (0.72) | HTR2BCHRM4HTR7DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL7816888 | 0.99 | HTR2B (0.74) | HTR2BCHRM4HTR7DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL7816431 | 0.99 | HTR2B (0.74) | HTR2BCHRM4HTR7DRD2HTR2A | |
| SCHEMBL29462336 | 0.84 | HTR2B (0.98) | HTR2BCHRM4HTR7DRD2HTR2A | |
| SCHEMBL11043054 | 0.84 | HTR2B (0.98) | HTR2BCHRM4HTR7DRD2HTR2A | |
| SCHEMBL9391684 | 0.84 | HTR2B (0.98) | HTR2BCHRM4HTR7DRD2HTR2A | |
| SCHEMBL8771830 | 0.84 | HTR2B (0.66) | HTR2BCHRM4HTR7DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL29727825 | 0.84 | HTR2B (1.00) | HTR2BCHRM4HTR7DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL7828661 | 0.84 | HTR2B (1.00) | HTR2BCHRM4HTR7DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL7808526 | 0.83 | HTR2B (0.68) | HTR2BCHRM4HTR7DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5760051-A | CENTRAL NERVOUS SYSTEM | ELI LILLY AND COMPANY (US) | 1998-06-02 | — | — | US | claimed |
| EP-0749313-A4 | METHOD FOR TREATING 5HT 2B RECEPTOR RELATED CONDITIONS | LILLY CO ELI (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6090945-A | HIGH AFFINITY FOR THE 5-HT1C RECEPTOR. | ELI LILLY AND COMPANY (US) | 2000-07-18 | — | — | US | disclosed |
| US-5635528-A | RECEPTOR BINDING MODULATORS, FOR CENTRAL NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1997-06-03 | — | — | US | disclosed |
| EP-0749313-A1 | METHOD FOR TREATING 5HT 2B RECEPTOR RELATED CONDITIONS | ELI LILLY AND COMPANY (US) | 1996-12-27 | — | — | EP | disclosed |
| US-5508284-A | TREATING 5-HYDROXYTRYPTAMINE MODULATION | ELI LILLY AND COMPANY (US) | 1996-04-16 | — | — | US | disclosed |
| US-5500431-A | ANTISEROTONINE AGENTS; SEXUAL AND EATING DISORDERS | ELI LILLY AND COMPANY (US) | 1996-03-19 | — | — | US | disclosed |
| WO-1995024200-A1 | METHOD FOR TREATING 5HT2B RECEPTOR RELATED CONDITIONS | ELI LILLY AND COMPANY (US) | 1995-09-14 | — | — | WO | disclosed |
| WO-1994023720-A1 | TETRAHYDRO-BETA-CARBOLINES | ELI LILLY AND COMPANY (US) | 1994-10-27 | — | — | WO | disclosed |
| EP-0620222-A2 | Tetrahydro-beta-carbolines | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |